Form 4: Rhythm Pharma Grants EVP 35,000 Stock Options

Rhythm Pharmaceuticals' EVP, Head of International, Yann Mazabraud, was granted 35,000 stock options with an exercise price of $94.94.

Summary

• Yann Mazabraud, Executive Vice President and Head of International for Rhythm Pharmaceuticals, Inc. (RYTM), was granted 35,000 stock options.
• The stock options were granted on March 2, 2026, with an exercise price of $94.94 per share.
• These options will vest and become exercisable in 16 substantially equal installments upon the completion of each three full months of successive service to the Issuer following the grant date.
• The expiration date for these stock options is March 1, 2036.
• Following this transaction, Yann Mazabraud beneficially owns 35,000 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating continued executive commitment and a standard compensation practice that aligns management incentives with shareholder value.

Positives

• The grant of stock options aligns the executive's financial interests with those of shareholders, incentivizing long-term performance.
• This compensation structure is a standard practice for attracting and retaining key executive talent within the pharmaceutical industry.

Future Outlook

The vesting schedule of the stock options, occurring in 16 substantially equal installments over successive three-month periods, indicates an expectation of continued service from Yann Mazabraud to Rhythm Pharmaceuticals.

Industry Context

StockSavvy.ai notes that stock option grants are a common form of executive compensation across the biotechnology and pharmaceutical sectors. This practice is designed to align the interests of management with those of shareholders by tying a portion of executive pay to the company's stock performance.

Comparison to Industry Standards

• StockSavvy.ai notes that option grants are standard practice across the biotech and pharmaceutical industries to attract and retain executive talent.
• The specific grant size and exercise price would typically be benchmarked against peer companies for similar roles, though this filing does not provide such comparative data.

Related Party Transactions

• Grant of 35,000 stock options to Yann Mazabraud, EVP, Head of International, as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of stock options can positively impact shareholders by aligning executive incentives with long-term company performance and stock appreciation.
• Employees: This type of compensation can contribute to executive retention and overall stability within the leadership team.

Next Steps

• The stock options will vest in 16 substantially equal installments upon Yann Mazabraud's completion of each three full months of successive service to the Issuer following the grant date.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to an executive as part of their compensation package. While it aligns management incentives with shareholder value, it does not provide new fundamental information about the company's operational performance or strategic direction that would alter an investment thesis. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Rhythm Pharmaceuticals, RYTM, stock options, insider transaction, executive compensation, Form 4, Yann Mazabraud